» Articles » PMID: 11228542

Imaging Proteolysis by Living Human Breast Cancer Cells

Overview
Journal Neoplasia
Publisher Elsevier
Specialty Oncology
Date 2001 Mar 3
PMID 11228542
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant progression is accompanied by degradation of extracellular matrix proteins. Here we describe a novel confocal assay in which we can observe proteolysis by living human breast cancer cells (BT20 and BT549) through the use of quenched-fluorescent protein substrates. Degradation thus was imaged, by confocal optical sectioning, as an accumulation of fluorescent products. With the BT20 cells, fluorescence was localized to pericellular focal areas that coincide with pits in the underlying matrix. In contrast, fluorescence was localized to intracellular vesicles in the BT549 cells, vesicles that also label for lysosomal markers. Neither intracellular nor pericellular fluorescence was observed in the BT549 cells in the presence of cytochalasin B, suggesting that degradation occurred intracellularly and was dependent on endocytic uptake of substrate. In the presence of a cathepsin B-selective cysteine protease inhibitor, intracellular fluorescence was decreased approximately 90% and pericellular fluorescence decreased 67% to 96%, depending on the protein substrate. Matrix metallo protease inhibitors reduced pericellular fluorescence approximately 50%, i.e., comparably to a serine and a broad spectrum cysteine protease inhibitor. Our results suggest that: 1) a proteolytic cascade participates in pericellular digestion of matrix proteins by living human breast cancer cells, and 2) the cysteine protease cathepsin B participates in both pericellular and intracellular digestion of matrix proteins by living human breast cancer cells.

Citing Articles

Decoding physical principles of cell migration under controlled environment using microfluidics.

Suh Y, Li A, Pandey M, Nordmann C, Huang Y, Wu M Biophys Rev (Melville). 2024; 5(3):031302.

PMID: 39091432 PMC: 11290890. DOI: 10.1063/5.0199161.


Modelling the Tumor Microenvironment: Recapitulating Nano- and Micro-Scale Properties that Regulate Tumor Progression.

Vahala D, Choi Y Front Cell Dev Biol. 2022; 10:908799.

PMID: 35800896 PMC: 9254080. DOI: 10.3389/fcell.2022.908799.


Polydopamine-modified ROS-responsive prodrug nanoplatform with enhanced stability for precise treatment of breast cancer.

Yang B, Wang K, Zhang D, Ji B, Zhao D, Wang X RSC Adv. 2022; 9(16):9260-9269.

PMID: 35517686 PMC: 9062053. DOI: 10.1039/c9ra01230c.


Cathepsin B Localizes in the Caveolae and Participates in the Proteolytic Cascade in Trabecular Meshwork Cells. Potential New Drug Target for the Treatment of Glaucoma.

Nettesheim A, Shim M, Dixon A, Raychaudhuri U, Gong H, Liton P J Clin Med. 2020; 10(1).

PMID: 33379277 PMC: 7795952. DOI: 10.3390/jcm10010078.


Oxidation-strengthened disulfide-bridged prodrug nanoplatforms with cascade facilitated drug release for synergetic photochemotherapy.

Yang B, Wei L, Wang Y, Li N, Ji B, Wang K Asian J Pharm Sci. 2020; 15(5):637-645.

PMID: 33193865 PMC: 7610204. DOI: 10.1016/j.ajps.2019.09.001.


References
1.
Buck M, Karustis D, Day N, Honn K, Sloane B . Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. Biochem J. 1992; 282 ( Pt 1):273-8. PMC: 1130919. DOI: 10.1042/bj2820273. View

2.
Via L, Fratti R, McFalone M, Deretic D, Deretic V . Effects of cytokines on mycobacterial phagosome maturation. J Cell Sci. 1998; 111 ( Pt 7):897-905. DOI: 10.1242/jcs.111.7.897. View

3.
Guinec N, Pagano M . "In vitro" study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol Chem Hoppe Seyler. 1993; 374(12):1135-46. DOI: 10.1515/bchm3.1993.374.7-12.1135. View

4.
Abrahamson M, Mason R, Hansson H, Buttle D, Grubb A, Ohlsson K . Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase. Biochem J. 1991; 273 ( Pt 3):621-6. PMC: 1149809. DOI: 10.1042/bj2730621. View

5.
Murata M, Miyashita S, Yokoo C, Tamai M, Hanada K, Hatayama K . Novel epoxysuccinyl peptides. Selective inhibitors of cathepsin B, in vitro. FEBS Lett. 1991; 280(2):307-10. DOI: 10.1016/0014-5793(91)80318-w. View